Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 198 trial

Journal of the National Cancer Institute

Volumn 104, Issue 16, 2012, Pages 1265-1266

  Stanton, Vincent ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; FORMALDEHYDE; PARAFFIN; TAMOXIFEN;

BREAST CANCER; COPY NUMBER VARIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; LETTER; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL; PSEUDOGENE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 84865476035     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs305     Document Type: Letter

References (6)

1. R egan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 2012;104(6):441-451.
2. R odriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009; 169(4):505-514. Web tool: http://www.oege. org/software/hwe-mr-calc.shtml. Accessed July 4, 2012.
3. Benetkiewicz M, Piotrowski A, Díaz, et al. Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol. 2006;29(4):935-945.
4. R ae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics. 2003;13(8):501-507. (Pubitemid 37034592)
5. Ahern TP, Christensen M, Cronin-Fenton DP, et al. Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. J Clin Epidemiol. 2010;2:241-246.
6. R ae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.